Reviewers: Li Liu, MD
Source: Blood, 93(11), June 1999
Data on prognostic factors of primary cutaneous lymphomas (PCL) other than mycosis fungoides (MF) and the S?zary Syndrome (SS) has been lacking. The well-established factors associated with poor prognosis for nodal lymphomas may not hold true for PCL. Grange and associates conducted this study to test the clinical validity of the EORTC classification and to identify important prognostic factors of survival in patients with non-MF/SS PCL.
A retrospective review of one hundred and fifty-eight patients, median age 68, with diagnoses of non-MF/SS PCL was performed. PCL was defined by the absence of extracutaneous disease detected at the time of diagnosis. Univariate and multivariate analyses for many possible prognostic factors were performed.
Optimal treatments of non-MF/SS PCL remain undefined. Radiation therapy alone can be used in patients with localized CD30 positive large T-cell lymphomas and localized indolent B-cell lymphomas. Multi-agent chemotherapy is more suitable for patients with more advanced disease.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2016 Trustees of The University of Pennsylvania